The global point of care molecular diagnostics market is witnessing strong expansion as healthcare systems increasingly prioritize rapid, accurate, and accessible diagnostic solutions. The market is estimated to reach USD 7.09 billion by 2030 from USD 4.30 billion in 2025, growing at a CAGR of 10.5% during the forecast period.
The increasing burden of infectious diseases, rising prevalence of cancer, growing demand for early disease detection, and the transition toward decentralized healthcare models are key factors accelerating market growth. Point-of-care molecular diagnostics (POC molecular diagnostics) enable healthcare professionals to perform advanced molecular testing near patients, reducing turnaround time and supporting faster treatment decisions.
The adoption of portable molecular platforms, automated testing systems, cartridge-based solutions, and isothermal amplification technologies is transforming diagnostic workflows across hospitals, clinics, emergency care centers, and remote healthcare settings.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=143524127
Growing Need for Rapid and Accurate Diagnostic Testing Drives Market Growth
The increasing incidence of infectious diseases has significantly contributed to the rising demand for point-of-care molecular diagnostics. Respiratory infections, sexually transmitted infections, gastrointestinal infections, and emerging infectious diseases require rapid detection to prevent transmission and enable timely treatment.
Traditional laboratory-based molecular testing often requires sample transportation and longer processing times. Point-of-care molecular diagnostic systems overcome these limitations by delivering accurate results directly at healthcare facilities or near patients.
The COVID-19 pandemic further accelerated the adoption of rapid molecular testing platforms by highlighting the importance of decentralized diagnostics. Healthcare providers, governments, and diagnostic companies increased investments in portable molecular testing technologies to improve outbreak preparedness and disease surveillance.
In addition, the growing prevalence of cancer has increased the need for molecular diagnostics that support early detection, biomarker identification, and personalized treatment strategies. These factors continue to strengthen the demand for POC molecular diagnostic solutions.
Technological Advancements Transforming Point of Care Molecular Diagnostics
Innovation in molecular diagnostic technologies is one of the major factors driving the expansion of the market. Manufacturers are developing compact, automated, and user-friendly diagnostic platforms that enable high-performance molecular testing outside centralized laboratories.
Advanced technologies such as:
- Reverse transcription polymerase chain reaction (RT-PCR)
- Isothermal nucleic acid amplification technology (INAAT)
- Integrated sample-to-answer systems
- Multiplex molecular testing platforms
- Automated cartridge-based diagnostics
are improving the accessibility and reliability of point-of-care testing.
These technologies reduce the complexity of molecular testing by combining sample preparation, amplification, detection, and result interpretation into a single platform. This enables healthcare professionals with minimal laboratory expertise to perform accurate molecular diagnostics.
The integration of digital connectivity, artificial intelligence, and cloud-based data management is also enhancing the efficiency of point-of-care molecular diagnostics by enabling remote monitoring, data sharing, and improved clinical decision-making.
RT-PCR Segment Dominates Point of Care Molecular Diagnostics Market
Based on technology, the point-of-care molecular diagnostics market is segmented into RT-PCR, INAAT, and other technologies. Among these, the RT-PCR segment accounted for the largest market share in 2024.
RT-PCR remains a widely adopted molecular diagnostic technology due to its high sensitivity, specificity, and proven clinical performance. It plays a critical role in detecting infectious diseases by identifying genetic material from pathogens with high accuracy.
The availability of compact and portable RT-PCR systems has further expanded its application beyond centralized laboratories. Hospitals, emergency departments, outpatient clinics, and decentralized healthcare centers are increasingly adopting RT-PCR-based solutions for faster diagnosis.
Continuous improvements in workflow automation, reduced testing time, and enhanced assay performance are expected to support the continued dominance of RT-PCR technology in the coming years.
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=143524127
Hospitals Lead Adoption of Point of Care Molecular Diagnostics
By end user, the point-of-care molecular diagnostics market is segmented into physicians’ offices and clinics, hospitals, research institutes, and other healthcare settings.
The hospitals segment held the largest market share in 2024, driven by increasing patient volumes and the growing need for rapid diagnostic decision-making.
Hospitals require fast and reliable diagnostic solutions, especially in emergency departments, intensive care units, infectious disease management, and oncology departments. Point-of-care molecular diagnostics help healthcare providers initiate appropriate treatment quickly, reduce patient waiting time, and improve clinical outcomes.
The adoption of decentralized testing capabilities within hospitals is also increasing as healthcare organizations aim to reduce pressure on centralized laboratories and improve operational efficiency.
Furthermore, hospitals are investing in advanced molecular diagnostic platforms to support personalized medicine, infection control programs, and precision healthcare initiatives.
North America Dominates the Point of Care Molecular Diagnostics Market
North America accounted for the largest share of the global point-of-care molecular diagnostics market in 2024.
The region’s leadership is supported by advanced healthcare infrastructure, strong adoption of innovative diagnostic technologies, significant investments in healthcare research, and the presence of leading diagnostic companies.
The United States remains a major contributor due to:
- High healthcare expenditure
- Increasing demand for rapid diagnostics
- Strong presence of biotechnology and diagnostic companies
- Growing adoption of decentralized healthcare models
- Supportive regulatory environment
The availability of advanced healthcare facilities, specialized medical centers, and trained healthcare professionals has enabled widespread integration of point-of-care molecular testing solutions into routine clinical practice.
Emerging Opportunities in Decentralized Healthcare
The shift toward decentralized healthcare delivery is creating significant opportunities for the point-of-care molecular diagnostics market.
Healthcare systems worldwide are focusing on improving diagnostic accessibility in rural and underserved regions. Portable and easy-to-use molecular diagnostic devices are helping bridge healthcare gaps by enabling testing closer to patients.
Emerging economies are increasingly adopting POC molecular diagnostic platforms due to expanding healthcare infrastructure, rising disease burden, and growing investments in diagnostic technologies.
The increasing focus on preventive healthcare, personalized medicine, and home-based testing is expected to create new growth opportunities for market participants.
Competitive Landscape
The point-of-care molecular diagnostics market is highly competitive, with companies focusing on product innovation, strategic partnerships, geographic expansion, and advanced technology development.
Key players operating in the market include Danaher Corporation, bioMérieux, F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN N.V., QuidelOrtho Corporation, Co-Diagnostics Inc., Biocartis Group NV, SD Biosensor, genedrive plc, Binx Health, Molbio Diagnostics, Genomadix, Visby Medical, QuantuMDx Group, DetectaChem, Akonni Biosystems, Ubiquitome, Credo Diagnostics Biomedical, OpGen, Nuclein, Genes2Me, Axxin, and Huwel Lifesciences.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=143524127
Future Outlook
The future of the point-of-care molecular diagnostics market remains highly promising as healthcare providers continue shifting toward faster, more accessible, and patient-centric diagnostic approaches.
Growing infectious disease concerns, rising cancer incidence, technological advancements, and increasing adoption of decentralized testing solutions will continue driving market expansion. With ongoing innovation in molecular platforms, automation, and digital healthcare integration, point-of-care molecular diagnostics are expected to become a critical component of next-generation healthcare delivery worldwide.